MANE · Veradermics, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · MANE
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $20.93M | - | - | - |
| SG&A | $1.47M | - | - | - |
| Total Operating Expenses | $12.91M | - | - | - |
| D&A | - | - | - | - |
| Operating Income | ($29.86M) | - | - | - |
| Interest Expense | - | - | - | - |
| Income Tax | $0 | - | - | - |
| Net Income | ($12.40M) | - | - | - |
| EPS - Basic | ($1.32) | - | - | - |
| EPS - Diluted | ($19.79) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Cash & Equivalents | $168.41M | $21.77M | $53.08M | $16.30M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $1.07M | $2.13M | $2.25M | - |
| Current Assets | $397.07M | $152.49M | $55.53M | - |
| Total Assets | $397.36M | $152.62M | $55.53M | - |
| Current Liabilities | $6.72M | $9.15M | $4.72M | - |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $6.72M | $9.16M | $4.72M | - |
| Stockholders' Equity | $390.64M | ($121.01M) | ($48.48M) | ($22.24M) |
| Retained Earnings | ($150.65M) | ($123.42M) | ($49.23M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Operating Cash Flow | ($21.17M) | - | - | - |
| Investing Cash Flow | ($15.75M) | - | - | - |
| Financing Cash Flow | $8.42M | - | - | - |
| CapEx | $0 | - | - | - |
| Free Cash Flow | ($21.17M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 1.71 | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -3.1% | - | - | - |
| Return on equity | -3.2% | - | - | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 59.12 | 16.66 | 11.77 | - |
| Quick ratio | 59.12 | 16.66 | 11.77 | - |
| Cash ratio | 25.08 | 2.38 | 11.25 | - |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | 1.02 | -1.26 | -1.15 | - |
| Liabilities / Assets | 0.02 | 0.06 | 0.08 | - |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 0.1x | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | -149.6% | -118.0% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Veradermics against the 5 most active filers in the same SIC group.